J'Neka S Claxton1, Alanna M Chamberlain2, Pamela L Lutsey3, Lin Y Chen4, Richard F MacLehose3, Lindsay G S Bengtson5, Alvaro Alonso6. 1. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Ga. Electronic address: j'neka.claxton@emory.edu. 2. Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. 3. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis. 4. Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis. 5. Health Economics and Outcomes Research, Life Sciences, Optum, Eden Prairie, Minn. 6. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Ga.
Abstract
BACKGROUND: The burden imposed by multimorbidity on outcomes and on the effectiveness of atrial fibrillation therapies in elderly adults with atrial fibrillation is unknown. METHODS: Patients with nonvalvular atrial fibrillation ages ≥75 years in the MarketScan Medicare Supplemental database from 2007-2015. Prevalence of 14 chronic conditions at the time of atrial fibrillation diagnosis were obtained and classified as cardiometabolic or noncardiometabolic. Cox regression estimated the associations of the number and type of conditions with stroke, severe bleeding, and heart failure hospitalizations. Tests for interaction were assessed between atrial fibrillation treatments and multimorbidity. RESULTS: Among 275,617 patients with atrial fibrillation (mean age 83 years, 51% women), the mean (SD) number of conditions per participant was 3.0 (2.1). Over a mean follow-up of 23 months, 7814 strokes, 13,622 severe bleeds, and 19,252 heart failure events occurred. After adjustment, an increase in the number of cardiometabolic conditions was associated with greater risk of stroke (hazard ratio [HR] 1.07; 95% confidence interval [CI], 1.05-1.10), severe bleeding (HR 1.09; 95% CI, 1.07-1.11), and heart failure (HR 1.19, 95% CI, 1.18-1.20). In contrast, number of noncardiometabolic conditions had weak or null associations with risk of cardiovascular endpoints. Overall, the effectiveness of atrial fibrillation treatment on stroke and heart failure were similar across multimorbidity status, but bleeding risk associated with atrial fibrillation treatments was higher in patients with overall and subgroup multimorbidity. CONCLUSION: Cardiometabolic multimorbidity was associated with worse outcomes and modified bleeding risk in atrial fibrillation patients. These findings underscore the impact of cardiometabolic conditions on atrial fibrillation outcomes and highlights the need to incorporate multimorbidity management in atrial fibrillation treatment guidelines.
BACKGROUND: The burden imposed by multimorbidity on outcomes and on the effectiveness of atrial fibrillation therapies in elderly adults with atrial fibrillation is unknown. METHODS: Patients with nonvalvular atrial fibrillation ages ≥75 years in the MarketScan Medicare Supplemental database from 2007-2015. Prevalence of 14 chronic conditions at the time of atrial fibrillation diagnosis were obtained and classified as cardiometabolic or noncardiometabolic. Cox regression estimated the associations of the number and type of conditions with stroke, severe bleeding, and heart failure hospitalizations. Tests for interaction were assessed between atrial fibrillation treatments and multimorbidity. RESULTS: Among 275,617 patients with atrial fibrillation (mean age 83 years, 51% women), the mean (SD) number of conditions per participant was 3.0 (2.1). Over a mean follow-up of 23 months, 7814 strokes, 13,622 severe bleeds, and 19,252 heart failure events occurred. After adjustment, an increase in the number of cardiometabolic conditions was associated with greater risk of stroke (hazard ratio [HR] 1.07; 95% confidence interval [CI], 1.05-1.10), severe bleeding (HR 1.09; 95% CI, 1.07-1.11), and heart failure (HR 1.19, 95% CI, 1.18-1.20). In contrast, number of noncardiometabolic conditions had weak or null associations with risk of cardiovascular endpoints. Overall, the effectiveness of atrial fibrillation treatment on stroke and heart failure were similar across multimorbidity status, but bleeding risk associated with atrial fibrillation treatments was higher in patients with overall and subgroup multimorbidity. CONCLUSION: Cardiometabolic multimorbidity was associated with worse outcomes and modified bleeding risk in atrial fibrillation patients. These findings underscore the impact of cardiometabolic conditions on atrial fibrillation outcomes and highlights the need to incorporate multimorbidity management in atrial fibrillation treatment guidelines.
Authors: Renu K Garg; Nicole L Glazer; Kerri L Wiggins; Katherine M Newton; Evan L Thacker; Nicholas L Smith; David S Siscovick; Bruce M Psaty; Susan R Heckbert Journal: Pharmacoepidemiol Drug Saf Date: 2010-12-23 Impact factor: 2.890
Authors: Jonathan P Piccini; Bradley G Hammill; Moritz F Sinner; Paul N Jensen; Adrian F Hernandez; Susan R Heckbert; Emelia J Benjamin; Lesley H Curtis Journal: Circ Cardiovasc Qual Outcomes Date: 2012-01-10
Authors: Joyce C LaMori; Samir H Mody; Hillary J Gross; Marco daCosta DiBonaventura; Aarti A Patel; Jeffrey R Schein; Winnie W Nelson Journal: Ther Adv Cardiovasc Dis Date: 2012-10-22
Authors: Amit Noheria; Peter Shrader; Jonathan P Piccini; Gregg C Fonarow; Peter R Kowey; Kenneth W Mahaffey; Gerald Naccarelli; Peter A Noseworthy; James A Reiffel; Benjamin A Steinberg; Laine E Thomas; Eric D Peterson; Bernard J Gersh Journal: JACC Clin Electrophysiol Date: 2015-11-26
Authors: J'Neka S Claxton; Richard F MacLehose; Pamela L Lutsey; Faye L Norby; Lin Y Chen; Wesley T O'Neal; Alanna M Chamberlain; Lindsay G S Bengtson; Alvaro Alonso Journal: PLoS One Date: 2018-09-10 Impact factor: 3.240
Authors: Hawa O Abu; Jane Saczynski; Jordy Mehawej; Tenes Paul; Hamza Awad; Benita A Bamgbade; Isabelle C Pierre-Louis; Mayra Tisminetzky; Catarina I Kiefe; Robert J Goldberg; David D McManus Journal: BMC Geriatr Date: 2020-09-11 Impact factor: 4.070